Amendment: SEC Form SC 13G/A filed by Solventum Corporation
$SOLV
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $70.00 | Neutral | Mizuho |
| 10/8/2024 | $82.00 | Buy | Stifel |
| 10/7/2024 | $71.00 | Neutral | Piper Sandler |
| 9/26/2024 | Peer Perform | Wolfe Research | |
| 9/5/2024 | Neutral | BTIG Research | |
| 6/24/2024 | Hold | Argus | |
| 5/30/2024 | $54.00 | Sell | Goldman |
Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli
ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025, beginning at approximately 2:20 p.m. PST in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest chal
ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646
10-Q - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00
Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00
Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00
Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli
ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646
Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3%GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41Generated $219 million in cash from operations; free cash flow of $92 millionIntroduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 27, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter ended December 31, 2024. "Solventum executed another quarter of solid performance, enabling us to deliver full year 2024 at the high end of our ex
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza
ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi